PCNA
Overview
PCNA (Proliferating Cell Nuclear Antigen) is an essential sliding clamp for DNA polymerase delta, functioning in DNA replication and repair. In glioma, PCNA has been identified as a transcriptional target of HOXD13 and serves as a prognostic indicator of cell proliferation and tumor aggressiveness.
Alterations observed in the corpus
- PCNA is a target gene of HOXD13 in IDH-mutant astrocytoma progression; PCNA upregulation is associated with treatment-related epigenetic demethylation and the transition to an aggressive, IDH-wildtype-like phenotype at recurrence PMID:38117484.
- PCNA is cited as a prognostic indicator in gliomas and a potential therapeutic target within the HOXD13 transcriptional network PMID:38117484.
Cancer types (linked)
- IDH-mutant astrocytoma (DIFG, ASTR) — PCNA upregulated downstream of HOXD13 activation at recurrence, particularly in treatment-exposed tumors PMID:38117484.
Co-occurrence and mutual exclusivity
- PCNA co-upregulation with HOXD13 and CENPF characterizes treatment-associated recurrent IDH-mutant gliomas PMID:38117484.
Therapeutic relevance
- PCNA is a candidate therapeutic target in recurrent IDH-mutant glioma; its upregulation downstream of HOXD13 suggests that HOXD13 pathway inhibition could reduce PCNA-driven proliferation PMID:38117484.
Open questions
- Direct functional validation of PCNA as a therapeutic target in IDH-mutant glioma models is lacking; most evidence is from transcriptional profiling and CRISPR KO of upstream HOXD13.
Sources
This page was processed by crosslinker on 2026-05-04.